Work

A phase I trial of ALKS 4230, an engineered cytokine activator of NK and effector T cells, in patients with advanced solid tumors.

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.tps3111

Authors: Ulka N. Vaishampayan, Marc S. Ernstoff, Vamsidhar Velcheti, Christopher J. Hoimes, Mayer N. Fishman, Daniel C. Cho, David F. McDermott, Michael R. Kurman, Juan Alvarez, Lei Sun, William Slichenmyer, Sean Rossi

Institutions: Wayne State University, Cleveland Clinic, Case Comprehensive Cancer Center, Case Western Reserve University, Moffitt Cancer Center, Beth Israel Deaconess Medical Center, Alkermes (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890052683

Cites:

Cited by: 5

Related to: 10